IAS Gyan

Daily News Analysis

Respiratory Syncytial Virus

23rd August, 2023 Health

Disclaimer: Copyright infringement not intended.

Context: USFDA gives nod to the first vaccine named ABRYSVO to protect newborns from Respiratory Syncytial Virus.

Respiratory Syncytial Virus (RSV) vaccine

  • The new vaccine is made by Pfizers.
  • It is given to mothers late in their pregnancies.
  • It protects infants through their first six months of life.

About Respiratory Syncytial Virus (RSV)

  • Also called human respiratory syncytial virus and human metapneumovirus, it is a common, contagious virus that causes infections of the respiratory tract.
  • It is a negative-sense, single-stranded RNA virus.
  • RSV is a common cause of illness in children, and infants are among those at highest risk for severe disease.
  • It also leads to a large number of hospitalisations.
  • It typically hits hardest during the winter months.
  • The last RSV season was longer and more severe than usual, overwhelming children’s hospitals.

Importance of the RSV vaccine’s approval

  • This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease.
  • There are many vaccines to protect people from RSV. There are new vaccines also available for people 60 and older.
  • However, the recently approved antibody shot can protect infants after birth from the illness.
  • ABRYSVO’s approval is the first and only maternal immunization to help protect newborns immediately at birth through six months.
  • Pfizer has said that maternal vaccination could prevent up to 16,000 hospitalizations and more than 300,000 visits to the doctor due to RSV each year.


Q) The term  “ABRYSVO” recently seen in the news relates to which of the following?

  1. A vaccine
  2. A newly discovered exoplanet by NASA
  3. Recently launched lunar satellite by France
  4. Naval exercise between India and France

Choose the correct option.

Ans: A